newsfilter
← Latest News
GlobeNewswire·

Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update

All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff da